XML 52 R14.htm IDEA: XBRL DOCUMENT
v3.20.1

RELATED PARTY TRANSACTIONS | 3 Months Ended
--- | ---
Mar. 31, 2020
RELATED PARTY TRANSACTIONS |
NOTE 8 - RELATED PARTY TRANSACTIONS | On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in common stock and additional paid-in capital). Doc Pharma S.A. As of March 31, 2020, the Company has a prepaid balance of €2,127,745 ($2,343,924) and an accounts payable balance of €30,526 ($33,627), resulting in a net prepaid balance of €2,097,219 ($2,310,296) to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of €326,696 and £168,633 ($569,903). As of December 31, 2019, the Company has a prepaid balance of €2,181,780 ($2,403,449) and an accounts payable balance of €22,576 ($24,870), resulting in a net prepaid balance of €2,158,434 ($2,377,731) to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of €546,240 ($601,738). During the three months ended March 31, 2020 and 2019, the Company has purchased a total of €608,448 ($670,631) €507,389 ($576,089) of products from Doc Pharma, respectively. During the three months ended March 31, 2020 and 2019, Skypharm and Cosmofarm had €132,368 ($145,896) €158,828 ($183,333) revenue from Doc Pharma, and Decahedron had revenue £168,633 ($215,648) from Doc Pharma, respectively. Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma SA in the past. Notes Payable – Related Party A summary of the Company’s related party notes payable during the three months ended March 31, 2020 and the year ended December 31, 2019 is presented below:
|  | 2020 |  |  | 2019 |
Beginning Balance |  | $ | 1,375,532 |  |  | $ | 1,793,437 |
Payments |  |  | (3,305 | ) |  |  | (382,055 | )
Foreign currency translation |  |  | (25,851 | ) |  |  | (35,850 | )
Ending Balance |  | $ | 1,346,376 |  |  | $ | 1,375,532 |
Grigorios Siokas On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum and has a maturity date of March 18, 2019. As of December 31, 2019, the note had an outstanding principal balance of €1,200,000 ($1,347,240) and accrued interest of €124,281 ($139,530). As of March 31, 2020, the Company has an outstanding balance of €1,200,000 ($1,321,920) and accrued interest of €138,345 ($152,401). Grigorios Siokas is the Company’s CEO and principal shareholder. Dimitrios Goulielmos On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan is non-interest bearing. During the year ended December 31, 2019, the Company repaid €40,300 ($45,245) and a principal balance of €13,200 ($14,820) remained as of December 31, 2019. During the three months ended March 31, 2020, the Company repaid €3,000 ($3,305) and a principal balance of €10,200 ($11,237) remained as of March 31, 2020. Dimitrios Goulielmos is a current director and former CEO of the Company. DOC Pharma On November 1, 2015, the Company entered into a €12,000 ($12,662) Loan Agreement with Doc Pharma S.A, pursuant to which Doc Pharma S.A., paid existing bills of the Company in the amount of €12,000 ($12,662), excluding the Vendor Bills. The loan bears an interest rate of 2% per annum and was due and payable in full on October 31, 2016. As of December 31, 2019, the Company has an outstanding principal balance of €12,000 ($13,472) and accrued interest expense of $1,100. As of March 31, 2020, the Company has an outstanding principal balance of €12,000 ($13,219) and accrued interest expense of $1,166. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2020 the Company recorded losses of $25,851. Loans Payable – Related Party A summary of the Company’s related party loans payable during the three months ended March 31, 2020, and the year ended December 31, 2019 is presented below:
|  | 2020 |  |  | 2019 |
Beginning Balance |  | $ | 1,026,264 |  |  | $ | 1,775,251 |
Proceeds |  |  | 516,819 |  |  |  | 585,915 |
Payments |  |  | (49,572 | ) |  |  | (262,226 | )
Conversion of debt |  |  | - |  |  |  | (1,050,000 | )
Reclassification of receivable |  |  | - |  |  |  | 2,547 |
Foreign currency translation |  |  | (5,704 | ) |  |  | (25,223 | )
Ending Balance |  | $ | 1,487,807 |  |  | $ | 1,026,264 |
Grigorios Siokas From time to time Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2019, the Company had an outstanding principal balance under these loans of $1,026,264 consisting of €297,314 ($303,502) and $722,762, in loans payable to Grigorios Siokas. During the three months ended March 31, 2020, the Company borrowed additional proceeds of €124,200 ($136,819) and $380,000 and repaid €45,000 ($49,572) of these loans. As of March 31, 2020, the Company had an outstanding balance under these loans of $1,487,807. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2020 the Company recorded losses of $5,704. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI http://asc.fasb.org/topic&trid=2122745 + Details
Name: | us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration